Top

Published in:

01-09-2018 | Images in Hematology

Severe acyclovir-resistant herpes simplex virus 1 infection following cord blood transplantation

Authors: Tomonari Shigemura, Yozo Nakazawa, Tomoki Yoshikawa, Hikaru Fujii, Souichi Yamada, Masayuki Saijo, Ryuhei Okuyama

Published in: International Journal of Hematology | Issue 3/2018

Excerpt

A 13-year-old girl with chronic active Epstein–Barr virus infection received unrelated cord blood transplantation (CBT) after a preparative regimen comprising rabbit antithymocyte globulin (ATG, 2.5 mg/kg/day for 2 days), fludarabine (30 mg/m²/day for 6 days), melphalan (70 mg/m²/day for 2 days), and total body irradiation (2 Gy/day for 2 days). Tacrolimus and methylprednisolone were used for graft-versus-host disease prophylaxis. Intravenous acyclovir (ACV) was infused at 10 mg/kg twice a day for prophylaxis against herpes simplex virus (HSV) infection. …

Kawamura K, Hayakawa J, Akahoshi Y, Harada N, Nakano H, Kameda K, et al. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015;102(2):230–7.CrossRefPubMed

Schmidt S, Bohn-Wippert K, Schlattmann P, Zell R, Sauerbrei A. Sequence analysis of herpes simplex virus 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may be relevant for development of antiviral resistance. Antimicrob Agents Chemother. 2015;59(8):4938–45.CrossRefPubMedPubMedCentral

Title: Severe acyclovir-resistant herpes simplex virus 1 infection following cord blood transplantation
Authors: Tomonari Shigemura
Yozo Nakazawa
Tomoki Yoshikawa
Hikaru Fujii
Souichi Yamada
Masayuki Saijo
Ryuhei Okuyama
Publication date: 01-09-2018
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-018-2480-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2018

Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation

Safety of intra-articular transplantation of lentivirally transduced mesenchymal stromal cells for haemophilic arthropathy in a non-human primate

Comprehensive molecular diagnosis of Epstein–Barr virus-associated lymphoproliferative diseases using next-generation sequencing

A case of primary familial congenital polycythemia with a novel EPOR mutation: possible spontaneous remission/alleviation by menstrual bleeding

CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients

Impact of hospital length of stay on the risk of readmission and overall survival after allogeneic stem cell transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer